1. Home
  2. ACRS vs PDCC Comparison

ACRS vs PDCC Comparison

Compare ACRS & PDCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ACRS
  • PDCC
  • Stock Information
  • Founded
  • ACRS 2012
  • PDCC N/A
  • Country
  • ACRS United States
  • PDCC
  • Employees
  • ACRS N/A
  • PDCC N/A
  • Industry
  • ACRS Biotechnology: Pharmaceutical Preparations
  • PDCC
  • Sector
  • ACRS Health Care
  • PDCC
  • Exchange
  • ACRS Nasdaq
  • PDCC NYSE
  • Market Cap
  • ACRS 127.6M
  • PDCC 136.9M
  • IPO Year
  • ACRS 2015
  • PDCC N/A
  • Fundamental
  • Price
  • ACRS $1.14
  • PDCC N/A
  • Analyst Decision
  • ACRS Strong Buy
  • PDCC
  • Analyst Count
  • ACRS 7
  • PDCC 0
  • Target Price
  • ACRS $11.67
  • PDCC N/A
  • AVG Volume (30 Days)
  • ACRS 968.2K
  • PDCC N/A
  • Earning Date
  • ACRS 05-06-2025
  • PDCC N/A
  • Dividend Yield
  • ACRS N/A
  • PDCC N/A
  • EPS Growth
  • ACRS N/A
  • PDCC N/A
  • EPS
  • ACRS N/A
  • PDCC N/A
  • Revenue
  • ACRS $18,720,000.00
  • PDCC N/A
  • Revenue This Year
  • ACRS N/A
  • PDCC N/A
  • Revenue Next Year
  • ACRS $425.96
  • PDCC N/A
  • P/E Ratio
  • ACRS N/A
  • PDCC N/A
  • Revenue Growth
  • ACRS N/A
  • PDCC N/A
  • 52 Week Low
  • ACRS $0.95
  • PDCC N/A
  • 52 Week High
  • ACRS $5.17
  • PDCC N/A
  • Technical
  • Relative Strength Index (RSI)
  • ACRS 27.21
  • PDCC N/A
  • Support Level
  • ACRS $1.05
  • PDCC N/A
  • Resistance Level
  • ACRS $1.23
  • PDCC N/A
  • Average True Range (ATR)
  • ACRS 0.11
  • PDCC 0.00
  • MACD
  • ACRS -0.01
  • PDCC 0.00
  • Stochastic Oscillator
  • ACRS 16.82
  • PDCC 0.00

About ACRS Aclaris Therapeutics Inc.

Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.

About PDCC PEARL DIVER CREDIT COMPANY INC

PEARL DIVER CREDIT COMPANY INC is a non-diversified closed ended management investment company.

Share on Social Networks: